<DOC>
	<DOCNO>NCT00371605</DOCNO>
	<brief_summary>A fixed-dosing regimen voriconazole routinely use prophylaxis aspergillosis liver transplant patient admit transplant intensive care unit UPMC . We hypothesize use fixed-dosing regimen voriconazole lead large degree variability drug exposure among liver transplant patient due : 1 ) variability absorption elimination cause physiological characteristic unique patient population 2 ) non-linear pharmacokinetics 3 ) potential polymorphism gene encode cytochrome P-450 enzyme metabolize voriconazole . This pilot clinical pharmacokinetic evaluation : 1 ) characterize plasma concentration versus time profile voriconazole liver transplant patient receive fixed-dosing regimen assess extremes systemic exposure 2 ) determine oral bioavailability voriconazole liver transplant patient 3 ) ass functionally significant allelic variation cytochrome P-450 enzyme metabolize voriconazole ( CYP2C9 , CYP2C19 CYP3A4/5 ) recipient blood allograft tissue may contribute extreme systemic exposure among liver transplant patient . This evaluation allow assessment adequacy prophylactic regimen achieve therapeutic drug concentration subject . Additionally , utility genotyping clinical tool identify patient risk extreme voriconazole exposure evaluate . The characterization pharmacokinetics liver transplant patient may utilize define optimal therapeutic regimen individualize target specific concentration maximize efficacy minimize side-effects .</brief_summary>
	<brief_title>An Assessment Voriconazole Pharmacokinetics Pharmacogenetics Liver Transplant Recipients - Pilot Study</brief_title>
	<detailed_description>All liver transplant patient receive voriconazole prophylaxis eligible participate study . We propose single-center , observational study 15 liver transplant patient admit ICU receive voriconazole prophylaxis part standard care . Each patient undergo blood sampling ( 27 mL ) one occasion ( Pharmacokinetic Study I ) , receive oral voriconazole . A small portion blood ( 1 mL ) collect blood sample period retain genotyping ( specific aim III ) . Voriconazole prophylaxis often administer liver transplant patient via oral route ( 200 mg twice daily ) . However , circumstance may arise necessitate administration intravenous dos voriconazole subset patient , part standard care . . Thus , patient undergo blood sample maximum two additional occasion : 1 ) surround intravenous dose dose ( 27 mL ) 2 ) surround oral dose ( 27 mL ) . The amount voriconazole present blood sample measure via high pressure liquid chromatography . Individual plasma concentration time profile determine follow oral intravenous dosing , respectively . Pharmacokinetic parameter estimate derive via population individual pharmacokinetic data analysis . The use , dose , frequency medication voriconazole clinical staff . We alter delivery , dose use drug . Therefore provide request information depend clinical team . We intervene enroll subject . Subjects enrol placed voriconazole agree participate .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Consecutive male female liver transplant recipient , 18 year old , initiated voriconazole prophylactic regimen transplant physician part standard care , eligible inclusion study . Transplant recipients receive voriconazole treat active fungal infection exclude . Transplant recipient concurrently receive medication document affect voriconazole pharmacokinetics exclude . The agent include , may limit follow ; carbamazepine , phenytoin , omeprazole , rifabutin , rifampin , ketoconazole , itraconazole , fluconazole , St. John 's wort extract . Those require therapy protease inhibitor human immunodeficiency virus ( HIV ) infection may include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Liver Transplant</keyword>
	<keyword>Fungal Infection</keyword>
</DOC>